Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Haemophilus influenzae type b

Haemophilus influenzae type b

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Haemophilus influenzae type b

49 trials tracked for Haemophilus influenzae type b: 36 in phase 3 or 4 and 4 with published results. The most-cited published study has 18 citations.

49Trials tracked
36Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 6 Phase 3 30 Phase 2 13
  1. Phase 3 Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib Completed · 18 cited
  2. Phase 4 Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed · 12 cited
  3. Phase 4 Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Completed · 10 cited
  4. Phase 3 A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia Completed · 6 cited
  5. Phase 4 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed
  6. Phase 4 Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants Completed
Show 43 more trials
  1. Phase 4 Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study) Completed
  2. Phase 4 Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine Completed
  3. Phase 3 Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine Completed
  4. Phase 3 Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants Completed
  5. Phase 3 Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children Completed
  6. Phase 3 Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) Completed
  7. Phase 3 Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine Completed
  8. Phase 3 Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine Completed
  9. Phase 3 Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age Completed
  10. Phase 3 Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants Completed
  11. Phase 3 Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m Completed
  12. Phase 3 Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine Completed
  13. Phase 3 Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years. Completed
  14. Phase 3 Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine Completed
  15. Phase 3 Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age Completed
  16. Phase 3 Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants Completed
  17. Phase 3 Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV Completed
  18. Phase 3 Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers Completed
  19. Phase 3 Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants Completed
  20. Phase 3 Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC Completed
  21. Phase 3 Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age. Completed
  22. Phase 3 Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED) Completed
  23. Phase 3 Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine Completed
  24. Phase 3 Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ Completed
  25. Phase 3 Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants Completed
  26. Phase 3 Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months. Completed
  27. Phase 3 Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants Completed
  28. Phase 3 Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ Completed
  29. Phase 3 Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines Completed
  30. Phase 3 Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB Completed
  31. Phase 2 Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age Completed
  32. Phase 2 Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine Completed
  33. Phase 2 Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Completed
  34. Phase 2 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age Completed
  35. Phase 2 Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Completed
  36. Phase 2 Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines Completed
  37. Phase 2 Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants Completed
  38. Phase 2 Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers Completed
  39. Phase 2 Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants Completed
  40. Phase 2 Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine Completed
  41. Phase 2 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose Completed
  42. Phase 2 Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants Completed
  43. Phase 2 Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine Completed

Showing the 49 most-cited and recently-updated of 49 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
ACIP Updates Hib Vaccine Recommendations for American Indian and Alaska Native Infants
Allergy & Immunology
ACIP Updates Hib Vaccine Recommendations for American Indian and Alaska Native Infants Why are health officials updating vaccine guidance for Native American infants?
The Advisory Committee on Immunization Practices (ACIP) has issued updated recommendations for Haemophilus influenzae type b (Hib) vaccinati…
Health officials updated vaccine guidance to better protect American Indian and Alaska Native infants from a serious bacterial infection tha…
CDC Apr 3, 2026
MT-2301 Hib vaccine candidate shows efficacy in phase 2 study of 154 infants
Infectious Disease Phase II
MT-2301 Hib vaccine candidate shows efficacy in phase 2 study of 154 infants How well does a new Hib vaccine protect infants when given with other routine shots?
A phase 2 study evaluated the efficacy and safety of MT-2301 (Haemophilus b conjugate vaccine) co-administered with DPT-IPV in healthy infan…
A new Hib vaccine given with routine shots reached the same antibody protection levels as the current approved vaccine in healthy infants.
CT.gov Mar 30, 2026